Maksim Mamonkin, PhD

Dr. Mamonkin is a translational immunologist focused on engineering cell therapies for cancer and other grave diseases. Together with his team, he has developed chimeric antigen receptor (CAR) T cells targeting CD5, CD7, and other antigens in leukemia and lymphoma and translated them to first-in-human clinical trials in patients with treatment-resistant cancers (NCT03081910, NCT03690011, NCT04219163, NCT07220993).

His laboratory develops new cell platforms for autologous and off-the-shelf therapies for hematologic, solid, and brain malignancies and engineers them for optimal activity and resistance to host immune rejection. Clinical translation of best approaches is the ultimate goal and a critical focus of Dr. Mamonkin’s team, paired with state-of-the-art correlative studies in patients treated with experimental cell therapies. Pediatric diseases are a special focus of the laboratory as Dr. Mamonkin directs translational development of pediatric cell therapies at Columbia.

While most projects are focusing on cancer therapies, research interests of the group extend beyond the malignancy into auto- and alloimmune diseases and regenerative medicine. The laboratory has been funded by numerous awards from NIH, LLS/BCU, Stand UP to Caner, CPRIT, CZ Biohub, and other mechanisms.